Celldex announces positive Phase 3 results for barzolvolimab in CSU
Celldex's barzolvolimab met primary and all secondary endpoints in Phase 3 trials for chronic spontaneous urticaria, leading to a potential FDA BLA submission in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed